Abstract

The Belgian biotech firm Galapagos has agreed to sell its contract research organization (CRO) Fidelta to the Polish CRO Selvita for about $38 million. Based in Croatia, Fidelta employs more than 150 chemists and other scientists who provide discovery services to drug industry customers. Galapagos sold its other CROs, BioFocus and Argenta, to Charles River Laboratories in 2014.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.